Do GLP-1s help with PCOS?

PCOS (polycystic ovary syndrome) affects roughly 1 in 10 women and runs on a self-reinforcing loop: insulin resistance drives androgen excess, androgens and hormonal chaos promote weight gain, and weight gain deepens insulin resistance. GLP-1s attack the loop at two points — weight and insulin sensitivity — which is why the gynecology and endocrinology worlds are increasingly interested. What the evidence shows so far: modest weight loss (5–10%) has long been known to restore ovulation and improve androgens in many women with PCOS; GLP-1s reliably deliver losses beyond that threshold. Small randomized trials (mostly exenatide and liraglutide; semaglutide data growing) show GLP-1s matching or beating metformin — PCOS’s traditional metabolic drug — on weight, insulin measures, and menstrual regularity, with combination therapy often best. Honest caveats: trials are small and short, semaglutide/tirzepatide-specific PCOS data is thinner than the enthusiasm, and no GLP-1 carries a PCOS indication — prescribing is off-label, usually justified through the standard BMI gates that many women with PCOS meet anyway. The practical realities for a woman with PCOS considering one: - Fertility can switch back on with little warning. Years of irregular cycles teach people they “can’t easily get pregnant”; weight loss un-teaches the body faster than it un-teaches the habit. Combined with reduced oral-contraceptive absorption during titration, unplanned pregnancy is a genuinely common PCOS-GLP-1 story — non-oral backup contraception during dose escalation is the standard advice, and conception plans mean stopping 2 months ahead. - Metformin coexists fine with GLP-1s (it’s the most common pairing); expect more GI grumble early. - The non-weight PCOS toolkit (cycle regulation, anti-androgens like spironolactone) still has its jobs; GLP-1s complement rather than replace it — sequencing belongs with your gynecologist or endocrinologist.